megestrol

P4, N=71, Active, not recruiting, University of Kansas Medical Center | Recruiting --> Active, not recruiting

P3, N=120, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.

Leptin is a reliable predictive marker for multitargeted anti-cachectic treatment outcomes. Thus, it can be an ideal candidate for monitoring and predicting the effects of anti-cachectic treatment and a surrogate marker of the immune-metabolic actions of the selected drugs.

P=N/A, N=10, Not yet recruiting, Peking University People's Hospital

Se sugiere utilizar bevacizumab u olaparib más bevacizumab en pacientes con CEO estadios III/IV BRCA1/2 negativo o desconocido (HRD positivo) que recibieron quimioterapia basada en platino más bevacizumab y obtuvieron RC/RP...Para pacientes con CEO de alto grado avanzado o metastásico en recaída platino-sensibles se sugiere: • Quimioterapia combinada basada en platino: carboplatino/doxorrubicina liposomal o carboplatino/paclitaxel o carboplatino/ nab-paclitaxel o carboplatino/docetaxel o carboplatino/gemcitabina, por seis ciclos. Si no se tolera la terapia combinada, dar carboplatino o cisplatino solo. • Quimioterapia combinada: carboplatino/gemcitabina o carboplatino/paclitaxel o carboplatino/doxorubicina liposomal, más bevacizumab, seguida de bevacizumab como mantenimiento (hasta progresión o toxicidad)...El paclitaxel semanal o la doxorrubicina liposomal pegilada o el topotecan pueden ser administrados con o sin bevacizumab. • Existen otros agentes que se consideran potencialmente act ivos (capecitabina, ciclofosfamida, ifosfamida, irinotecán, oxaliplatino, pemetrexed, vinorelbina, ciclofosfamida), que se podrían recomendar para líneas posteriores. • Las pacientes con receptores hormonales positivos que no toleran o no tienen respuesta a los regímenes citotóxicos pueden recibir terapia hormonal con tamoxifeno u otros agentes, incluidos los inhibidores de la aromatasa (anastrozol y letrozol) o acetato de leuprolide o acetato de megestrol...El niraparib podría ser útil en pacientes BRCA 1/2 +/-/desconocido, al igual que el rucaparib, sin embargo, este último no tiene aún aprobación del ente regulador en Colombia. Conclusiones: se espera que las recomendaciones emitidas en este consenso contribuyan a mejorar la atención clínica, el impacto oncológico y la calidad de vida de estas mujeres.

P3, N=300, Recruiting, Qingdao Central Hospital

P3, N=360, Recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Apr 2024 --> May 2026

P=N/A, N=75, Recruiting, Women's Hospital School Of Medicine Zhejiang University

P4, N=60, Recruiting, University of Kansas Medical Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

Retrospective cohort study collected data for patients with AEH or EMCA who had an endometrial sample after receiving conservative therapy utilizing either Megestrol acetate or Levonorgestrel Intrauterine device (IUD). Immunohistochemistry (IHC) was performed on pre- and post- treatment biopsy samples to assess androgen receptor (AR), estrogen receptor (ER), and progesterone receptor (PR) expression...Patients who successfully responded to the treatment demonstrated a significantly greater decrease in IHC scores after the treatment compared to those who did not respond (p = 0.009). Steroid receptor expression could be used as a possible biomarker for response to progestin therapy in patients undergoing conservative management for AEH and EMCA.

P2, N=104, Recruiting, Fudan University | Trial primary completion date: Mar 2024 --> Mar 2025

P1/2, N=96, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting

P4, N=126, Completed, Children's Hospital of Fudan University | Recruiting --> Completed

P2, N=198, Completed, Cambridge University Hospitals NHS Foundation Trust | Recruiting --> Completed

P2, N=48, Recruiting, Fudan University | Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2025

P2, N=50, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2024 --> Nov 2024 | Trial primary completion date: May 2024 --> Nov 2024

P2, N=44, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Dec 2023 --> Nov 2024 | Trial completion date: Dec 2023 --> Nov 2024

P1, N=54, Completed, Daewon Pharmaceutical Co., Ltd.

P1/2, N=96, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

Other reported targeted therapies for malignant GCTs included pazopanib in combination with crizotinib, which showed disease control for four months in one patient, and a PI3K inhibitor which achieved disease control for nine months in another patient. Dasatinib and megestrol were ineffective in two other different patients. Pazopanib has been demonstrated to be active in advanced GCTs and may be considered as a preferable treatment option.

P1/2, N=96, Recruiting, National Cancer Institute (NCI) | Phase classification: P2 --> P1/2

ESR1 mutations do not seem to be involved in the mechanisms of resistance to AI or M in HR+ endometrial cancer. The clinical relevance of their detection is not demonstrated.

P1, N=5, Terminated, Sunnybrook Health Sciences Centre | N=73 --> 5 | Trial completion date: Sep 2024 --> Oct 2023 | Recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Oct 2023; Slow enrollment

P2, N=50, Recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> May 2024 | Trial primary completion date: Oct 2023 --> May 2024

No differences in PFS and OS curves were observed; the CBR was 75.0% and 60.4%, respectively. (4) The association of EDP-M + megestrol acetate in ACC pts with a low PS is feasible and well tolerated; its efficacy appeared to be non-inferior to EDP-M administered to pts with a good PS.

This real-world data on RMEC suggests there is a role for progestins in select subgroups of women. The PFS for chemotherapy-naïve patients was 17.9 months (14.3, 27.0), versus 6.2 months (3.9, 14.8) following ≥1 line of treatment. The OS was 29.1 months (17.9, 61.1) for chemotherapy-OS was 29.1 months (17.9, 61.1) for chemotherapy-naïve patients versus 23.0 months (10.5, 37.6) for patients previously exposed.

The patient used Megestrol acetate 160 mg for 3 months...Following the procedure, the pathology report showed low-grade endometrial endometrioid carcinoma (FIGO grade 2).Conclusion Fertility-preserving approaches can be considered as a rare option for P53 Mutant Grade2 endometrioid endometrial cancer patients. However, as seen in our case, despite close monitoring, disease progression has been observed.

P=N/A, N=57, Recruiting, Peking University People's Hospital

The overall response rate to FST was promising, however, the PD rate was significant during the first 12 months of FST. Therefore, performing thorough endometrial biopsy and imaging studies is essential to strictly evaluate the extent of the disease every 3 months from FST initiation.

P2, N=80, Recruiting, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Two of her medications, gabapentin and mirtazapine were thought to be the contributors and were stopped upon admission, however with little improvement...She was ultimately started on hydrocortisone replacement therapy, with subsequent improvement and stabilization of her mental status, mood, and behavior; and was discharged with outpatient Endocrinology follow-up.This case highlights the importance of the broad differentials to consider for mental and behavioral changes...Megestrol is an established cause of secondary adrenal insufficiency, and monitoring is essential with long-term use.*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

Conclusions This study demonstrated that most patients with advanced gastrointestinal and pancreatobiliary cancer required MA prescription. The difference in the incidence of VTE was modest between the MA and non-MA prescription groups (not at the level of statistical significance on multivariate analyses).

Our results give support to the role of progesterone in ACC. The involvement of its analog (megestrol acetate) in reducing ACC progression in ACC patients undergoing EDP-M therapy is now under investigation in the PESETA phase II clinical study.

Methods Eligible patients (pts) had metastatic ER+ HER2- BC, and were randomized to receive MA or another HT agent (AHT), Tamoxifen or Exemestane, with 10 pts planned for each arm. Conclusions Translational analysis find evidence of increased transcriptional activity at ER regulated genes in most resistant samples. This could indicate that MA resistant tumours will retain sensitivity to further HT, requiring future research to proof this hypothesis.

P2, N=44, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=28 --> 44

P2, N=96, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting

Progestin therapy is a viable treatment option in patients with advanced stage and recurrent EC with low toxicity and high ORR in PR positive disease. The role of PR expression in relation to progression free survival and overall survival is unclear.

Eighty-four patients who took progestins (megestrol acetate, medroxyprogesterone acetate, and/or levonorgestrel-releasing intrauterine devices) were analyzed...The immunohistochemical markers evaluation looks promising in predicting response to conservative treatment. Further large series and randomized clinical trials are needed to confirm these results.

Methods This was a retrospective analysis of HR-positive, HER2-negative MBC patients who were treated with a combination of CT (capecitabine or oral cyclophosphamide) and HT (tamoxifen or aromatase inhibitor or fulvestrant or megestrol acetate) between Jan 2015 and Dec 2020, with data cutoff in May 2022. CHT was well tolerated with 21 (9.4%) patients experiencing any grade>/=3 toxicity. Conclusions Chemo-hormonal therapy is an effective treatment in heavily pre-treated MBC patients, including those with visceral metastases.

She was started on neoadjuvant chemotherapy (NACT) with carboplatin paclitaxel...Her disease recurred 12 months later and she received BEP (bleomycin, etoposide, cisplatin) for 4 cycles to obtain a partial response. On disease progression in October 2015, she was treated with pegylated liposomal doxorubicin (PLD) and carboplatin...She remained on megestrol acetate until the next progression in October 2018, and this time she opted for surgery...She was treated with Olaparib without any serious adverse events and had a disease control of 9 months. Unlike epithelial ovarian cancer (EOC) BRCA mutations have not been reported in aGCT. In our patient, multiple platinum-sensitive recurrences similar to EOC and subsequent finding of BRCA2 mutation makes a case for further investigation of such aberrations in aGCT with possible therapeutic implications.